Elevation Pharmaceuticals is a biopharmaceutical company developing new inhaled therapies for patients with respiratory disease. The company's initial focus is on developing novel therapies for the underserved population of COPD patients not able to effectively control their disease with dry powder or metered dose inhalers. Elevation's lead drug candidate is EP-101, an inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist bronchodilator, in Phase 2 studies for the improved treatment of patients with moderate to severe COPD.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/04/12 | $30,000,000 | Series B |
Canaan Partners Novo Ventures TPG Biotech | undisclosed |
